Prilocaine
From Wikipedia, the free encyclopedia
 |
|
|
Prilocaine
|
|
| Systematic (IUPAC) name | |
| N-(2-methylphenyl)-2-propylamino-propanamide | |
| Identifiers | |
| CAS number | |
| ATC code | N01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C13H20N2O |
| Mol. mass | 220.311 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 55% |
| Metabolism | Hepatic and renal |
| Half life | 10-150 minutes, longer with impaired hepatic or renal function |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B (U.S.) |
| Legal status | |
| Routes | ? |
Prilocaine (pronounced /ˈpraɪloʊkeɪn/) is a local anesthetic of the amino amide type. In its injectable form (trade name Citanest), it is often used in dentistry. It is also often combined with lidocaine as a preparation for dermal anesthesia (lidocaine/prilocaine or EMLA). As it has low cardiac toxicity, it is commoly used for intravenous regional anaesthesia (IVRA).
In some patients, a metabolite of prilocaine may cause the unusual side-effect of methaemoglobinaemia. And may be treated with methylene blue.
Maximum dosage for dental use: 6.0mg/kg (2.7mg/lb), with a maximum dose of 400mg.
|
||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
